Abstract
Introduction Tafasitamab, is a humanized, Fc-modified anti-CD19 monoclonal antibody that functions as an immunotherapy through direct cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). Based on data from the ongoing, open-label, multicenter, single-arm, Phase II L-MIND study (NCT02399085; Salles, et al. Lancet Oncol 2020), tafasitamab in combination with lenalidomide (LEN) was granted accelerated approval in the US (2020) and conditional/accelerated approval by the EMA (2021) and other regulatory authorities for the treatment of adult patients with R/R DLBCL not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are ineligible for autologous stem cell transplant (ASCT). It is a preferred regimen in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for this setting. We have previously reported long-term, durable clinical activity for tafasitamab + LEN (Duell, et al. Haematologica 2021). Here, we report efficacy and safety data for tafasitamab + LEN in patients with R/R DLBCL enrolled on L-MIND who received treatment for ≥2 years and those in follow-up for ≥5 years. Methods Patients were aged ≥18 years with ASCT-ineligible R/R DLBCL, 1-3 prior systemic therapies (including ≥1 CD20-targeting regimen), and an Eastern Cooperative Oncology Group performance status of 0-2. Patients received 28-day cycles of tafasitamab (12 mg/kg IV), once weekly during Cycles 1-3, with a loading dose on Day 4 of Cycle 1, then every 2 weeks (Q2W) during Cycles 4-12. LEN (25 mg orally) was administered on Days 1-21 of Cycles 1-12. After Cycle 12, progression-free patients received tafasitamab Q2W until disease progression. Time-to-event, treatment response (Cheson 2007), and safety endpoints were assessed. Results At data cut-off (February 15, 2022), of the 81 patients in the full analysis set, 30 patients completed 12 cycles of tafasitamab + LEN and 4 patients discontinued LEN before 12 cycles; 27 (34%) received treatment for ≥2 years (median: 4.3 years). The proportion of patients who were primary refractory, refractory to previous therapy, or who had received prior ASCT were similar between patients who received treatment for ≥2 years and the full analysis set (Table 1). Of the 27 patients who received treatment for ≥2 years, 23 are confirmed alive, one was lost to follow-up, one died by unknown cause, and two died following adverse events (AEs) unrelated to study treatment. Thirteen patients remained on treatment; reasons for tafasitamab discontinuation after ≥2 years were progressive disease (n=4), patient/physician decision (n=8), and non-treatment-related fatal AEs (n=2: one each for COVID-19 and cardiovascular AE). Twelve patients have been in follow-up for ≥5 years, of whom six are still on treatment, while 6 had discontinued treatment although still in response. In patients who received treatment for ≥2 years, 23 had previously achieved a complete response (CR) as a best response and four had a partial response (PR), as assessed by the investigator (Figure 1); the 48-month overall survival (OS) rate was 92.6%; however, the median duration of response, progression-free survival, and OS have not been reached. In patients refractory to previous therapy line (n=12), 91.7% were in follow-up at 48 months. All of the primary refractory patients (n=4) are in follow-up at 60 months. Of the six patients who received treatment for ≥5 years, five achieved CR (one of whom had triple-hit R/R DLBCL) and one had a PR (investigator-assessed). A lower incidence of AEs was reported during the tafasitamab monotherapy phase (Cycles 13-24 and Cycles ≥25) compared with the tafasitamab + LEN combination therapy phase (Cycles 1-12). The exposure-adjusted incidence of AEs showed that the majority were Grade 1-2. Conclusion Combination therapy with tafasitamab plus lenalidomide followed by tafasitamab monotherapy provided durable responses in patients with R/R DLBCL ineligible for ASCT. These long-term data suggest that this immunotherapy can achieve prolonged remission and survival of 5 years or longer in this patient population. The incidence of AEs decreased as patients transitioned from combination therapy to tafasitamab monotherapy, with long-term tafasitamab (up to 60 months) being well tolerated with no new safety signals. Funding MorphoSys AG Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have